S&P reaffirms Sirtex after new offer from Chinese manager
ASX-listed healthcare firm Sirtex, whose investors include some of Australia's leading fund managers, will remain in the S&P/ASX 200 after its US takeover has been postponed in light of a new offer.

LoginGo Premium

Read more: SirtexUSASXS&PAustraliaCDH InvestmentsUS-based Varian Medical SystemsBNP ParibasCarpe Diem Asset ManagementFederal CourtForeign Investment Review BoardHSBCIDP EducationJ.P. MorganWilliam Roberts LawyersYarra Capital
Link to something sDe6UZo0